Tscan Therapeutics is trading at $0.98 (-5.09%) as the biotech group continues to soften alongside broader risk-off sentiment.
- No new company-specific catalysts were identified in July 14 coverage to explain the downward move following a weak July 13 session.
- Recent gains tied to TSC-101 optimism appear to be meeting profit-taking pressure as investors pull back.
- The stock's decline reflects broader sector-wide weakness rather than a change in fundamental outlook.